Autolus Therapeutics plc Contract with Customer, Liability, Noncurrent
Autolus Therapeutics plc (AUTL) had Contract with Customer, Liability, Noncurrent of $253.44 million as of 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2025-05-08
- 2025-03-31: Contract with Customer, Liability, Noncurrent $253.44M.
- 2024-12-31: Contract with Customer, Liability, Noncurrent $244.60M.
- 2024-09-30: Contract with Customer, Liability, Noncurrent $248.94M.
- 2024-06-30: Contract with Customer, Liability, Noncurrent $238.66M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2025-03-31 | $253.44M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $244.60M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $248.94M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $238.66M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $228.49M 10-Q · filed 2024-05-17 |
| 2023-12-31 | $170.90M 10-K · filed 2025-03-20 |
| 2023-09-30 | $140.78M 10-K · filed 2024-03-21 |
| 2023-06-30 | $135.76M 10-K · filed 2024-03-21 |
| 2023-03-31 | $130.81M 10-K · filed 2024-03-21 |
| 2022-12-31 | $125.90M 10-K · filed 2024-03-21 |
| 2022-09-30 | $52.44M 10-K · filed 2024-03-21 |
| 2022-06-30 | $50.62M 10-K · filed 2024-03-21 |
| 2022-03-31 | $48.81M 10-K · filed 2024-03-21 |
| 2021-12-31 | $47.02M 20-F · filed 2023-03-07 |
| 2020-12-31 | $0.00 20-F · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |